Long-term Survival Data from Longeveron's ELPIS 1 Trial

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Japan ,Miami ,Florida ,American ,Mike Moyer ,Sunjay Kaushal ,National Institute Of Health Heart ,Nasdaq ,Drug Administration ,Blood Institute ,Longeveron Inc ,Company Quarterly ,Longeveron Or Company ,National Heart ,Exchange Commission ,Scientific Sessions Of The American Heart Association ,Extended Follow Up Data Show Continued ,Transplant Free Survival ,Support Continued Investigation ,Aging Related Frailty ,Scientific Sessions ,American Heart Association ,Long Term Transplant Free Survival Is Improved ,Hypoplastic Left Heart Syndrome ,Cell Based Therapy ,Chief Science Officer ,Single Ventricle Reconstruction ,Rare Pediatric Disease Designation ,Fast Track Designation ,Orphan Drug Designation ,Glenn Procedure ,National Institute ,Englj Med ,Private Securities Litigation Reform Act ,Quarterly Reports ,Nasdaq Lgvn ,Longeveron ,